Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 9 of 9
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Comparison of Adverse Events Between Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma in Mongolia: A Subgroup Analysis of SIRveNIB Study
    (Mongolian National University of Medical Sciences, 2017-11-25) ; ;
    Bolormaa Yalhgar
    ;
    Tuyatsetseg Altankhuyag
    ;
    Objective: This study compared the adverse events associated with selective internal radiation therapy to sorafenib in the treatment of patients with locally advanced hepatocellular carcinoma (HCC). Methods: From March 2011 to June 2106, the National Cancer Center of Mongolia recruited 39 patients from Mongolia (19 received sorafenib and 20 received SIRT in Singapore) with advanced hepatocellular carcinoma who had not received surgical therapy into a multicenter study involving a total of 360 patients at 27 sites in 11 Asia-Pacific countries. The study was a phase III randomized-controlled clinical trial comparing sorafenib or SIRT. Results: Adverse events for patients receiving sorafenib were predominantly grade 1 or 2 in gastrointestinal, constitutional and dermatologic in nature. The most frequently reported drug-related adverse events in patients treated with sorafenib were hypertension, hand-foot skin reaction, diarrhea, alopecia, fatigue. Common procedure-related adverse events were usually mild (grade 1/2) and included nausea and vomiting (27.7% all grades) and abdominal pain (22.1% all grades), with very few grades 3 or greater adverse events. Conclusion: In our analysis of 39 patients, we were unable to detect a statistically significant difference in adverse effects between sorafenib and SIRT treatment groups, likely because there were insufficient number patients in our study.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia
    (2018) ; ;
    Munkh-Orshikh, Dashchirev
    ;
    ;
    Sarangua, Ganbold
    Mongolia is located between Russia and China. The total population of Mongolia as of December 2017 is estimated to be 3.2 million people. According to our previous study results, the prevalence of HBV was 11.8%, and anti-HDV was detected in 4.8% among the HBsAg-positive subjects. Interestingly, most HCV infection is caused by genotype 1b. Among all HBV DNA-positive samples, 98.5% were classified into genotype D, and regarding HDV genotypes, all HDV RNA-positive samples, 100%, were classified into genotype I. The second study is the baseline survey of a Nationwide Cancer Cohort Study. Prevalence of HBsAg was 10.6%. Additionally, HCV infection was observed in 9.9%, and 0.8% were coinfected with HBV and HCV among the general population aged from 10 to 64 years. The third study investigated the population-based prevalence of hepatitis B and C virus in apparently healthy population of Ulaanbaatar city, Mongolia. The anti-HCV prevalence was 9.0%. In addition, the prevalence of HBV was 8.0%. The fourth study is on the prevalence of HCV and coinfections among nurses in a tertiary hospital in Mongolia. The prevalence of HCV was 18.9%. Additionally, HBV infection was observed in 23.1%, and 1.2% were coinfected with HCV and HBV. Mongolia has the highest HCC incidence in the world (78.1/100,000, 3.5* higher than China). As a result, the Mongolia government has launched The National Viral Hepatitis Program, which is a comprehensive program that involves all aspects from prevention to care and disease control to meet a reduction goal for morbidity and mortality due to HBV, HCV, and HDV. Consequently, access to antiviral therapies is now improving in Mongolia. How to cite this article: Baatarkhuu O, Gerelchimeg T, Munkh-Orshikh D, Batsukh B, Sarangua G, Amarsanaa J. Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian J Hepato-Gastroenterol 2018;8(1):57-62.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    ALBI Score for Predicting Acute Liver Failure in Patients with Acute Hepatitis B and D in Mongolia
    (Mongolian National University of Medical Sciences, 2021-04-01) ; ; ;
    Objectives: Mongolia is known as one of the countries with a high prevalence of hepatitis B and D virus infection. Although the number of acute hepatitis D cases is decreasing since the national vaccination program against HBV launched in 1991, it is still a main cause of acute liver failure (ALF) in Mongolia. The aim of this study is to determine the prognostic value of an ALBI score in patients with acute hepatitis B with or without D. Methods: A total of 114 patients (58 patients with acute hepatitis B (AHB), five patients with HBV/HDV co-infection, and 51 patients with HBV/HDV superinfection), who were admitted to the National Center for Communicable Diseases between 2017 and 2019 were enrolled into this study. Results: We compared the AHB group to the HBV/HDV superinfection group. The mean age was 25.8±6.5 years in the AHB group vs. 28.9±7.4 years in the HBV/HDV superinfection group (p = 0.019). Also, a majority of patients live in Ulaanbaatar (87.5% vs. 62.7%, p = 0.037). The mean hospitalization days was 23± 11 in the AHB, on the other hand it was 28± 13 in the HBV/HDV superinfection group (p = 0.022). The ALF patients had a higher ALBI score, total bilirubin, transaminase, and INR compared with the non-ALF group. The platelet count was significantly lower in the AHB and HBV/HDV infection group with ALF compared with AHB and HBV/HDV infection without ALF. This study showed that the ALBI score in AHB with ALF patients was significantly higher than in AHB without ALF (p = 0.001 ), and H BV/HDV superinfection with ALF had a higher ALBI score than HBV/HDV superinfection without ALF (p = 0.041 ). The area under the curve (AUC) value was 0.766 for ALBI scores. The cut-off value, sensitivity and specificity of ALBI score values were -1. 71, 72.2%, and 75.6%, respectively. Conclusions: ALBI score determined on admission indicates the likelihood of survival of patients with AHB and AHD.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Effectiveness of Cognitive Behavioral Therapy on Multi-drug Resistant Tuberculosis Patients in Mongolia: 10 years experiences
    (Mongolian National University of Medical Sciences, 2024-06-30) ; ; ;
    Anuzaya Purevdagva
    ;
    Kyung Hyun Oh
    Objective: During multidrug-resistant tuberculosis (MDR-TB) treatment, patients face de­pression and anxiety. This study aims to evaluate the effects of cognitive behavioral therapy (CBT) on the psychological status and risk of loss to follow-up (LTFU) during MDR-TB treat­ment in Mongolia. Method: Eligible participants were randomly assigned to intervention and control groups. Intervention group participants underwent CBT, while control group par­ticipants received standard patient education. Psychological status was assessed before and after CBT. MDR-TB treatment outcomes were evaluated as internationally defined. Results: The study included a total of 83 patients. After CBT, depression and anxiety levels decreased by 12% and 16%, respectively, in the intervention group, whereas the control group showed a 4% decrease in depression and an 8.5% increase in anxiety levels. MDR-TB treatment outcomes revealed an 8% higher treatment success rate and a fivefold reduction in LTFU rate in the intervention group compared to the control group. In multivariable logistic regression, risk factors associated with increased LTFU were living alone (OR 12.7, p=0.031) and not being provided CBT (OR 16.1, p=0.040). Conclusion: Our study suggests that CBT not only alleviates these psychological challenges but also diminishes the risk of LTFU during treat­ment, leading to improved MDR-TB treatment success.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Knowledge, Attitudes, and Practices (KAP) Regarding Hepatitis B Vaccination among Healthcare Workers in Mongolia
    (Scientific Research Publishing, 2023-01-01) ;
    Burmaajav Badrakh
    ;
    ;
    Byambaa Tumurbat
    ;
    Badamjav Amgalan
    Background: Mongolia is no exception and experiencing the burden of HBV among the population. In the last decade, the prevalence of HBV among the relatively healthy population of Mongolia has ranged between 11.8 percent and 10.6 percent, and acute cases are between 1.7 and 1.1 per 10,000 people. We aimed to determine healthcare workers (HCWs) knowledge, attitude, and practices regarding HBV prevention compared to vaccination coverage. Methods: This cross-sectional study was conducted among HCWs from the selected sites through multi-stage sampling. The study involved 1135 HCWs, including medical doctors, nurses, clinicians in both surgical and medical specialties, laboratory technicians, and other staff working in all departments from primary and referral levels in 36 healthcare facilities in two urban and four rural provinces of Mongolia. Participants who consented to the study completed a standardized self-administered questionnaire between July and Dec 2019. Results: Most participants (82.0%) were born before 1992 or before starting a birth vaccination against HBV in Mongolia. The mean age of the participants was 38 years and the participants’ median employment year in the health sector was seven years. Most participants were medical doctors (29.1%) and nurses (28.0%). Five questions explored HCWs’ knowledge about hepatitis B virus infection and prevention, and the correct response ranged between 15.6% and 95.4%. 2.8% of the respondents answered five questions correctly. Men, those with higher levels of education, those over the age of 30, soum family health center HCWs, and doctors and senior medical professionals answered many questions correctly, which is statistically significant. 98.9% of respondents believe that HCWs should vaccinate against HBV. The younger the age (%), management professionals, and service staff are confident in vaccines. A significant difference between age groups, perception of HBV infection, and formal attendance to the official training positively relate to vaccination coverage. Specially survey respondents who knew about the adverse effects of overdosing, learning about total doses of the vaccine, and the effectiveness of the hepatitis B vaccine were more tent to have full doses of the HBV vaccine. Knowledge and working conditions are increasing factors in receiving full doses of the HVB vaccine. Conclusion: The overall knowledge of HBV and its vaccination is fair among the HCWs; however, there is a need to intensify the training on some of the details and increase the training frequency at the workplace. Attitude and practice on infection protection and vaccination are still essential to be promoted among the HCWs. The low level of vaccination coverage is relevant to the level of KAP among the HCWs of the country.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Ледипасвир/Софосбувир эмчилгээнд хамрагдсан архаг С хепатиттай Монгол өвчтөнүүдэд Вирусын эсрэг шууд үйлдэлтэй эмийн тэсвэржилтийг судалсан судалгаа
    (2022-11-12) ;
    Ж.Амарсанаа
    ;
    Д.Энхтуяа
    ;
    Н.Наранзул
    ;
    Үндэслэл: Дэлхий дахинд вирусын эсрэг шууд үйлдэлтэй эм (ВЭШҮЭ)-ийг эмчилгээнд нэвтрүүлснээр эмчилгээний дараах вирусын тогтвортой хариу урвал (ВТХУ)-ын хувь харьцангуй өндөр байна. ХСВ-ийн 1б генотипийн архаг халдвартай өвчтнүүдэд Y93H цэгэн мутацийн улмаас тухайн генд кодлогдож буй уургийн 93 дахь амин хүчил тирозин (Y) нь гистидин (Н) болж өөрчлөгдөж, вирус ледипасвир эмэнд >1000 дахин тэсвэртэй болдог болох нь тогтоогдсон нь бидний судалгааны ажлыг хийх үндэслэл болж байна. Зорилго: Монгол улсад LDV/SOF эмчилгээнд хамрагдсан архаг С вируст хепатиттай өвчтөнүүдэд ВЭШҮЭ-ийн
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Hepatitis C Virus Infection in Mongolia: Updated Provincial Data on Prevalence, Genotype Distribution, and Age-Specific Risk Factors
    (MDPI AG, 2025-12) ;
    Baatarzorigt, Myagmarjaltsan
    ;
    Otgon, Munkhtuya
    ;
    ;
    (1) Background: Mongolia has historically reported one of the highest hepatitis C virus (HCV) prevalence rates globally, with past national estimates exceeding 15%, making HCV infection a major public health priority. This study aimed to assess the prevalence, genotype distribution, and risk factors of HCV infection among residents of Arkhangai Province. (2) Methods: This population-based cross-sectional study was conducted in 2022 including 2304 individuals aged 0-80 years. Serum samples were tested for anti-HCV antibodies using ELISA and for HCV RNA using PCR. Positive samples were genotyped, and demographic and exposure data were analyzed using logistic regression to identify independent risk factors. (3) Results: The prevalence of anti-HCV antibodies was 12.0%, and HCV RNA positivity was 7.16%. Infection increased significantly with age (p < 0.001) and was higher among females (14.6%) than males (8.4%). Genotype 1b predominated (98.2%), followed by 1a (1.2%) and 2 (0.6%). Several exposures showed strong associations with HCV infection in univariate analysis, including cupping therapy (OR 2.37, 95% CI 1.71-3.28), shared razor use (OR 2.39, 95% CI 1.59-3.60), cosmetic procedures (OR 1.70, 95% CI 1.11-2.45), and unsafe injections (OR 2.06, 95% CI 1.40-3.02). In multivariable analysis, four exposures remained independently associated with HCV infection: cupping therapy (adjusted OR 1.89, 95% CI 1.32-2.70), shared razor use (adjusted OR 1.98, 95% CI 1.24-2.89), cosmetic procedures (adjusted OR 1.62, 95% CI 1.39-2.24), and unsafe injections (adjusted OR 1.84, 95% CI 1.19-2.83). (4) Conclusions: HCV infection remains prevalent, particularly among older adults and women. Genotype 1b continues to predominate, indicating that the viral genetic distribution has remained largely unchanged over the past decade. Continued education, safe injection practices, and regulation of traditional and cosmetic procedures are essential to reduce HCV transmission and support Mongolia's elimination goals. These findings highlight the need for comprehensive prevention strategies addressing both unsafe traditional/medical practices and the rapidly expanding cosmetic and aesthetic service sector.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
    (The Korean Association for the Study of the Liver, 2021-01) ;
    Lee, Jae Seung
    ;
    Amarsanaa, Jazag
    ;
    ;
    Ahn, Sang Hoon
    BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. METHODS: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). RESULTS: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). CONCLUSION: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries.
    Scopus© Citations 5
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
    (Elsevier BV, 2020-03)
    Hsu, Shih-Jer
    ;
    ;
    Lin, You-Yu
    ;
    Tseng, Tai-Chung
    ;
    BACKGROUND: Mongolia has the highest prevalence of hepatitis C virus (HCV) infection worldwide. Ledipasvir/sofosbuvir (LDV/SOF) was introduced to Mongolia since 2016 for HCV eradication. It has been reported that HCV resistance-associated substitutions (RASs) would affect the effectiveness of LDV/SOF in western chronic hepatitis C (CHC) patients. We thus investigated the effectiveness of LDV/SOF and the impact of RAS on the treatment outcome in Mongolian CHC patients. METHODS: Patients with genotype (GT) 1b HCV infection were prospectively enrolled in Mongolia and treated with LDV/SOF for 12 weeks. The proportion of pre-treatment NS5A Y93H RAS in viral quasispecies was measured with next-generation sequencing. The endpoint of LDV/SOF effectiveness was sustained virological response at post-treatment week 12 (SVR12). RESULTS: A total of 94 CHC patients were evaluated. The baseline Y93H proportion was <1% in 74 patients, 1-15% in 7, 15-50% in 2, and ≥50% in 11. All patients completed 12-week LDV/SOF treatment and the SVR rate was 90.4%. The rate of failure to achieve SVR12 for patients with Y93H < 1%, 1-15%, and ≥15% were 0%, 14.3%, and 61.5%, respectively (p for trend = 0.001). In univariable analysis, older age, baseline alanine transaminase level <40 U/mL, and a higher proportion of Y93H were associated with treatment failure. In multivariable analysis, only a higher proportion of Y93H was associated with treatment failure (p = 0.022). CONCLUSION: LDV/SOF therapy achieves a high SVR rate in Mongolian CHC GT1b patients without baseline Y93H RAS. A higher proportion of Y93H may severely undermine the effectiveness of LDV/SOF.
    Scopus© Citations 5